Recent News

• 01.08.2026 - ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
• 01.07.2026 - ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
• 12.24.2025 - ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
• 11.13.2025 - ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025
• 11.06.2025 - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025
• 11.04.2025 - ImmuCell Announces Onboarding of New CEO and Related Management Changes

Recent Filings

• 01.08.2026 - EX-99.1 EX-99.1
• 01.08.2026 - 8-K Current report
• 12.29.2025 - EX-99.1 EX-99.1
• 12.29.2025 - 8-K Current report
• 12.04.2025 - 4/A Statement of changes in beneficial ownership of securities
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.20.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 11.13.2025 - 8-K Current report
• 11.13.2025 - EX-99.1 EX-99.1